OXALIPLATIN IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH CERVICAL CANCER

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这项I-II期研究的目的是确定局部复发或转移性宫颈癌患者的缓解率和毒性以及恢复情况。 该研究的基本原理是化疗/放疗对转移性（骨盆外）疾病患者的生存率没有改善。 顺铂是最有效的药物，但临床结果没有改善。 顺铂/紫杉醇可提高缓解率，但不能提高生存率。 研究人员现在将尝试奥沙利铂，奥沙利铂已被证明在一些顺铂耐药肿瘤中具有活性。 此外，奥沙利铂无显著肾毒性，该队列中肾脏受累的发生率较高。 研究的终点是可测量和不可测量的疾病;完全缓解、部分缓解等;毒性和恢复。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The aim of this phase I-II study is to determine the response rates and toxicities and recovery for patients with locally recurrent or metastatic cervical cancer. The rationale of the study is that there has been no improvement in survival in patients with metastatic (outside the pelvis) disease with chemotherapy/radiotherapy. Cisplatin has been the most active agent but has shown no improvement in clinical outcome. Cisplatinum/paclitaxel improves the response rate but not survival. The investigators will now try oxaliplatin, which has been shown to be active in some cisplatinum-resistant tumors. Also, there is no significant renal toxicity with oxaliplatin, and there has been a high incidence of renal involvement in this cohort. Endpoints of the study are measurable and non-measurable disease; complete response, partial response, etc; toxicity and recovery.